Risk of congenital toxoplasmosis in women with low or indeterminate anti-Toxoplasma IgG avidity index in the first trimester of pregnancy: an observational retrospective study.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 16 07 2018
revised: 28 09 2018
accepted: 30 09 2018
pubmed: 14 10 2018
medline: 23 8 2019
entrez: 14 10 2018
Statut: ppublish

Résumé

Congenital toxoplasmosis (CT) affects one to ten fetuses per 10 000 live newborns in western countries. Without knowing pre-conception serostatus, it is hard to date the infection when anti-Toxoplasma IgG and IgM antibodies are positive at first screening. Although a high IgG avidity index (AI) in the first trimester excludes CT, the same cannot be said of intermediate and low AI. The aim of this study was to estimate the risk of CT when intermediate or low AI is detected in the first trimester of pregnancy. Our observational retrospective study enrolled women with positive anti-Toxoplasma IgG and IgM, and low/intermediate AI in the first trimester of gestation seen at two reference centres in northern Italy between 2006 and 2015. All women received spiramycin. When requested by women, a sample of fluid obtained through amniocentesis was tested with a commercial real-time PCR. CT was defined by positive PCR result confirmed on aborted materials or by newborn follow up. Overall, 778 first-trimester pregnant women were included; AI was low in 532/778 (68%) and intermediate in 246/778 (32%). Amniocenteses were performed in 528/778 (67.9%), with no fetal loss. In all, 19/778 (2.4%) miscarriages and 15/778 (1.9%) pregnancy terminations were recorded; 9/778 (1.6%) were lost to follow up. In two women, PCR on amniotic fluid was positive, but CT was confirmed in only 1/747 cases (0.13%, 95% CI 0.02%-0.75%). In our study, the risk of CT was much lower than anticipated. These data must be considered when counselling these women.

Identifiants

pubmed: 30315959
pii: S1198-743X(18)30664-5
doi: 10.1016/j.cmi.2018.09.024
pii:
doi:

Substances chimiques

Antibodies, Protozoan 0
Immunoglobulin G 0

Types de publication

Journal Article Observational Study

Langues

eng

Pagination

761.e9-761.e13

Informations de copyright

Copyright © 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

L R Tomasoni (LR)

Department of Infectious and Tropical Diseases, Azienda Socio Sanitaria Territoriale Degli Spedali Civili di Brescia, Brescia, Italy. Electronic address: linatomasoni@yahoo.it.

G Messina (G)

Department of Infectious Diseases, Universita Degli Studi di Brescia Aree Disciplinari Medicina e Chirurgia, Brescia, Italy.

F Genco (F)

Sc Microbiologia e Virologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

L Scudeller (L)

Clinical Epidemiology Unit, Scientific Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

M Prestia (M)

Sc Microbiologia e Virologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

V Spinoni (V)

Department of Neonatology, Azienda Socio Sanitaria Territoriale Degli Spedali Civili di Brescia, Brescia, Italy.

C Bonfanti (C)

Department of Microbiology, Universita Degli Studi di Brescia Aree Disciplinari Medicina e Chirurgia, Brescia, Italy.

F Prefumo (F)

Department of Obstetrics and Gynaecology, Universita Degli Studi di Brescia Aree Disciplinari Medicina e Chirurgia, Brescia, Italy.

F Castelli (F)

Department of Infectious Diseases, Universita Degli Studi di Brescia Aree Disciplinari Medicina e Chirurgia, Brescia, Italy.

V Meroni (V)

Sc Microbiologia e Virologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Dipartimento di Medicina Interna e Terapia Medica, Universita Degli Studi di Pavia, Sc Microbiologia e Virologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH